title: Elucidating the genomic landscape of breast cancer: how will this affect treatment?
authors.affiliation: Bras Drug Development Program, Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, 5-125, 610 University Avenue, Toronto, ON M5G 2M9, Canada.
authors.forename: Neda
authors.initials: N
authors.lastname: Stjepanovic
authors.forename: Philippe L
authors.initials: PL
authors.lastname: Bedard
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D005260:Female; D018390:Gene Targeting / Q000639:trends; D023281:Genomics / Q000639:trends*; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases
keywords: CDK; ERBB2; ESR1; FGFR; PI3K pathway; breast cancer; homologous recombination deficiency